
Veracyte (VCYT) Stock Forecast & Price Target
Veracyte (VCYT) Analyst Ratings
Bulls say
Veracyte is a genomic diagnostics company with a diversified portfolio of tests for various types of cancer. Their latest test, TrueMRD, has demonstrated strong results in detecting cancer recurrence and has potential for a new immunotherapy monitoring indication. With planned and ongoing clinical studies and a solid financial foundation, the company has potential for double-digit growth and sustained revenue.
Bears say
Veracyte is a genomic diagnostics company that provides tests for prostate, thyroid, breast, and bladder cancer. Despite potential for upside to revenue and earnings estimates, there are several risks to Veracyte's stock, including weaker than expected sales, operating margins, and free cash flow. These risks, coupled with the company's small/mid-cap peers trading at lower EV/sales multiples, contribute to the financial analyst's negative outlook on Veracyte's stock.
This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.
Veracyte (VCYT) Analyst Forecast & Price Prediction
Start investing in Veracyte (VCYT)
Order type
Buy in
Order amount
Est. shares
0 shares